ATAIBECKLEY
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley dealEli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental...
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: ReportEli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge follow...
- Load More